Back to today’s briefing

Story perspectives

Eli Lilly's $1.3B Acquisition to Transform Heart Disease Treatment

6/20/2025

39 9

Summary

Story summary

Eli Lilly is set to acquire Verve Therapeutics for a staggering $1.3 billion, aiming to revolutionize gene-editing therapies for heart diseases. The deal features a cash offer of $10.50 per share, with potential bonuses. Verve's groundbreaking therapy, VERVE-102, targets cholesterol genes, promising a transformative one-time treatment. The acquisition is anticipated to finalize by Q3 2025.

1 of 1

Story summary

Eli Lilly is set to acquire Verve Therapeutics for a staggering $1.3 billion, aiming to revolutionize gene-editing therapies for heart diseases. The deal features a cash offer of $10.50 per share, with potential bonuses. Verve's groundbreaking therapy, VERVE-102, targets cholesterol genes, promising a transformative one-time treatment. The acquisition is anticipated to finalize by Q3 2025.